Vilastobart in combination with atezolizumab continued to demonstrate a differentiated and generally well-tolerated safety profile. Treatment-related adverse events (AEs) were primarily Grade 1 or 2, ...

Globalstar’s XCOM RAN brings a software-defined approach to the IT/OT challenge in Industry 4.0, via an open RAN private 5G ...

Record bookings growth for SonicWall’s strategic solutions highlights SonicWall’s evolution into a full-scale cybersecurity leader and trusted managed services partner.

NIMS has been developing chemical sensors as a key component of artificial olfaction technology (olfactory sensors), with the ...

Neoadjuvant therapy plays an increasingly important role in the multidisciplinary management of gastrointestinal cancers.

The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient ...

STCube, which is developing Nelmastobart, the first anti-BTN1A1 inhibitor, announced on November 10 that it has demonstrated ...

Introduction Adolescence is a key period of development for mental health; however, little is known about how (cumulative) daily life experiences impact long-term mental health development in this ...

Immunotherapy—could that be an option for me, doctor?” is a question frequently asked by patients with colorectal cancer. The ...

Gene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene ...

Jazz Pharmaceuticals plc  today announced that the company will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting taking place November 19-23 in Honolulu, Hawaii. The ...

Renalys will proceed with analyses of efficacy and safety data, as well as comparisons with global Phase 3 trial results, in preparation for the submission of a New Drug Application (NDA). As part of ...